Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment
Status:
Not yet recruiting
Trial end date:
2024-03-14
Target enrollment:
Participant gender:
Summary
The TRENT trial is designed to confirm the efficacy and safety of Gla-300 compared with
IDeg-100 in insulin-naïve patient (participants who have not tried insulin) with Type 2
Diabetes Mellitus (T2DM) and renal impairment. It will test the hypothesis that Gla-300 is
non-inferior to IDeg-100 with glucose control. If achieved, the trial will also test for the
superiority of Gla-300 compared with IDeg-100 in Hemoglobin A1c (HbA1c) reduction, without an
increased potential risk of hypoglycemia.